ARGX
argenx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Buy"
High Gross Profit Margin
Significant Net Income Growth
Revenue Beats Expectation
EPS Beats Expectation
Bearish Abandoned Baby
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ARGX
Argenx Se
A global immunology company that develops therapies to treat severe autoimmune diseases and cancer
Biological Technology
04/25/2008
05/18/2017
NASDAQ Stock Exchange
1,599
12-31
Depository Receipts (Ordinary Shares)
Laarderhoogtweg 25, NL-1101 EB Amsterdam, Netherlands
--
Argenx Se was established on 25 April 2008 under the laws of the Netherlands as a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid). On May 28, 2014, the company was converted into a public limited liability company (naamloze vennootschap) under the Notarized Conversion Deed and Amendment. The company is a commercial-stage, global, fully integrated biopharmaceutical company developing differentiated therapies for the treatment of severe autoimmune diseases.
Earnings Call
Q1/2025
Estimate EPS2.325725
Actual EPS2.58
Estimate Revenue836.27M
Actual Revenue814.56M
Argenx's Q1 2025: Unpacking Contradictions in Pricing Strategy, Market Share, and Regulatory Approvals
May 19,2025 09:15
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS3.06153
Actual EPS--
Estimate Revenue869.30M
Actual Revenue--
Argenx's Q2 2025 Earnings Call: Unraveling Key Contradictions in Medicare Impact, Patient Engagement, and Market Growth
Jul 31,2025 01:32
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ARGX has released its 2025 Q3 earnings. EPS was reported at 5.18, versus the expected 4.116784, beating expectations. The chart below visualizes how ARGX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ARGX has released its 2025 Q3 earnings report, with revenue of 1.15B, reflecting a YoY change of 95.51%, and net profit of 344.26M, showing a YoY change of 276.61%. The Sankey diagram below clearly presents ARGX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
